Market capitalization | $204.15m |
Enterprise Value | $353.25m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.80 |
P/S ratio (TTM) P/S ratio | 0.46 |
P/B ratio (TTM) P/B ratio | 4.51 |
Revenue growth (TTM) Revenue growth | -2.37% |
Revenue (TTM) Revenue | $444.20m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
4 Analysts have issued a Accuray Incorporated forecast:
4 Analysts have issued a Accuray Incorporated forecast:
Sep '24 |
+/-
%
|
||
Revenue | 444 444 |
2%
2%
|
|
Gross Profit | 138 138 |
13%
13%
|
|
EBITDA | 2.26 2.26 |
81%
81%
|
EBIT (Operating Income) EBIT | -3.86 -3.86 |
151%
151%
|
Net Profit | -17 -17 |
143%
143%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes cyberKnife and tomo therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.
Head office | United States |
CEO | Suzanne Winter |
Employees | 987 |
Founded | 1990 |
Website | www.accuray.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.